Pharmaceutical

Angle signs AstraZeneca deal to develop prostate cancer assay

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

May 5, 2024 - 00:00
Angle signs AstraZeneca deal to develop prostate cancer assay
UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.
Read the original article

Tags:

Previous Article

SCAI names James B. Hermiller, MD, MSCAI, President for 2024-25

Next Article

FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer

Pfizer and Genmab’s Tivdak wins full FDA approval for c...

May 1, 2024

Myricx Bio signs licence deal for WuXi Biologics’s antibody

Myricx Bio signs licence deal for WuXi Biologics’s anti...

Nov 22, 2023

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

ESC 2024: Beta blocker treatment paradigm shifts for my...

Sep 4, 2024